Chen Yao-Li, Chan Shih-Hsuan, Lin Ping-Yi, Chu Pei-Yi
School of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan; Department of General Surgery, Changhua Christian Hospital, Changhua, 50006, Taiwan; Transplantation Center, Third Xiangya Hospital of Central South University, Changsha, 410008, China.
Graduate Institute of Integrated Medicine, China Medical University, Taichung, 40402, Taiwan; Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, 35053, Taiwan.
Hum Pathol. 2017 May;63:212-216. doi: 10.1016/j.humpath.2017.03.003. Epub 2017 Mar 14.
The c-Jun dimerization protein 2 (JDP2) belongs to the activator protein-1 (AP-1) family and functions as a repressor of the AP-1 complex by dimerizing with other c-Jun proteins. Thus, JDP2 plays an important role in the repression of AP-1-driven biological processes, such as differentiation and proliferation. Recent studies have suggested that JDP2 may function as a tumor suppressor through its suppressive action against the AP-1 complex, which is known to drive oncogenic signals in several human malignancies. In this study, we used immunohistochemistry to examine the JDP2 expression in 211 cases of hepatocellular carcinoma (HCC) and analyzed the potential link of JDP2 expression to the clinicopathological features of HCC patients. Clinical parameter analysis showed that high expression of JDP2 was significantly correlated with smaller tumor size (P=.002) and early stage HCC (P=.039). Moreover, Kaplan-Meier survival analysis showed that high expression of JDP2 was significantly associated with better survival in HCC patients (P=.006). Taken together, our results showed that JDP2 may serve as a tumor suppressor in HCC and could therefore serve as a good prognostic marker for patients with HCC.
c-Jun二聚化蛋白2（JDP2）属于激活蛋白-1（AP-1）家族，通过与其他c-Jun蛋白二聚化发挥AP-1复合物阻遏物的作用。因此，JDP2在抑制AP-1驱动的生物学过程（如分化和增殖）中发挥重要作用。最近的研究表明，JDP2可能通过其对AP-1复合物的抑制作用发挥肿瘤抑制因子的功能，已知AP-1复合物在几种人类恶性肿瘤中驱动致癌信号。在本研究中，我们使用免疫组织化学方法检测了211例肝细胞癌（HCC）中JDP2的表达，并分析了JDP2表达与HCC患者临床病理特征之间的潜在联系。临床参数分析显示，JDP2高表达与肿瘤较小（P = 0.002）和早期HCC（P = 0.039）显著相关。此外，Kaplan-Meier生存分析显示，JDP2高表达与HCC患者更好的生存率显著相关（P = 0.006）。综上所述，我们的结果表明JDP2可能在HCC中作为肿瘤抑制因子发挥作用，因此可作为HCC患者良好的预后标志物。
